What do systematic reviews say?

Pharmacological agents vs placebo

• Pharmacotherapy for chronic cognitive impairment in traumatic brain injury 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 274 participants
  Very low

Donepezil 23 mg/day vs donepezil 10 mg/day

Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  OR 2.02 [1.59, 2.57]
  2 studies · 1818 participants
  Moderate

Donepezil 10 mg/day vs donepezil 5 mg/day

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  OR 1.67 [1.24, 2.23]
  3 studies · 1052 participants
  Moderate

Donepezil 10 mg/day vs placebo

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  OR 1.32 [1.02, 1.71]
  5 studies · 1396 participants
  Moderate

Donepezil 10 mg/day vs placebo

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).

• Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
  OR 1.25 [1.05, 1.5]
  12 studies · 2846 participants
  Moderate

Rivastigmine vs placebo

Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).

• Rivastigmine for Alzheimer's disease 2015 · Cochrane Headline outcomes only
  OR 2.01 [1.71, 2.37]
  7 studies · 3569 participants
  Moderate